Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary smallpox vaccination of adults

Vaccine

Volumn 24, Issue 47-48, 2006, Pages 6913-6923

  Treanor, John ^a   Wu, Hulin ^b   Liang, Hua ^b   Topham, David J ^c  

^a Division of Infectious Diseases   (United States)

^b Department of Biostatistics and Computational Biology ^*  (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Human; Immune; Vaccinia

Indexed keywords

GAMMA INTERFERON; SMALLPOX VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA; MALE; MYALGIA; NONHUMAN; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VACCINATION; VACCINIA;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; HUMANS; IMMUNITY, CELLULAR; INFLUENZA, HUMAN; INTERFERON TYPE II; KINETICS; MALE; MIDDLE AGED; SMALLPOX; SMALLPOX VACCINE; VACCINATION; VACCINIA; VACCINIA VIRUS;

EID: 33846223314     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.006     Document Type: Article

References (26)

1. Frey S.E., Couch R.B., Tacket C.O., Treanor J.J., Wolff M., Newman F.K., et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 346 17 (2002) 1265-1274
2. Demkowicz Jr. W.E., Littaua R.A., Wang J., and Ennis F.A. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 70 4 (1996) 2627-2631
3. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., and Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 171 10 (2003) 4969-4973
4. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 9 9 (2003) 1131-1137
5. Frey S.E., Newman F.K., Yan L., Lottenbach K.R., and Belshe R.B. Response to smallpox vaccine in persons immunized in the distant past. JAMA 289 24 (2003) 3295-3299
6. Crotty S., and Ahmed R. Immunological memory in humans. Semin Immunol 16 3 (2004) 197-203
7. Kennedy J.S., Frey S.E., Yan L., Rothman A.L., Cruz J., Newman F.K., et al. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis 190 7 (2004) 1286-1294
8. Ennis F.A., Cruz J., Demkowicz Jr. W.E., Rothman A.L., and McClain D.J. Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination. J Infect Dis 185 11 (2002) 1657-1659
9. Bennink J., Effros R.B., and Doherty P.C. Influenzal pneumonia: early appearance of cross-reactive T cells in lungs of mice primed with heterologous type A viruses. Immunology 35 3 (1978) 503-509
10. Allan W., Tabi Z., Cleary A., and Doherty P.C. Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells. J Immunol 144 10 (1990) 3980-3986
11. Newman F.K., Frey S.E., Blevins T.P., Mandava M., Bonifacio Jr. A., Yan L., et al. Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol 41 7 (2003) 3154-3157
12. Czerkinsky C., Andersson G., Ekre H.P., Nilsson L.A., Klareskog L., and Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods 110 1 (1988) 29-36
13. Amara R.R., Nigam P., Sharma S., Liu J., and Bostik V. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 78 8 (2004) 3811-3816
14. Eichner M. Analysis of historical data suggests long-lasting protective effects of smallpox vaccination. Am J Epidemiol 158 8 (2003) 717-723
15. Henderson D.A., Inglesby T.V., Bartlett J.G., Ascher M.S., Eitzen E., Jahrling P.B., et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281 22 (1999) 2127-2137
16. Ray S.J., Franki S.N., Pierce R.H., Dimitrova S., Koteliansky V., Sprague A.G., et al. The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. Immunity 20 2 (2004) 167-179
17. Walsh E.E., and Falsey A.R. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J Med Virol 73 2 (2004) 295-299
18. Deng Y., Jing Y., Campbell A.E., and Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 172 6 (2004) 3437-3446
19. Hou S., Hyland L., Ryan K.W., Portner A., and Doherty P.C. Virus-specific CD8+ T-cell memory determined by clonal burst size [see comments]. Nature 369 6482 (1994) 652-654
20. Mathew A., Ennis F.A., and Rothman A.L. Transient decreases in human T cell proliferative responses following vaccinia immunization. Clin Immunol 96 2 (2000) 100-107
21. Yang H.Y., Dundon P.L., Nahill S.R., and Welsh R.M. Virus-induced polyclonal cytotoxic T lymphocyte stimulation. J Immunol 142 5 (1989) 1710-1718
22. Selin L.K., and Welsh R.M. Specificity and editing by apoptosis of virus-induced cytotoxic T lymphocytes. Curr Opin Immunol 6 4 (1994) 553-559
23. Crotty S., Aubert R.D., Glidewell J., and Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 286 1-2 (2004) 111-122
24. Marennikova S.S. The use of hyperimmune antivaccinia gamma-globulin for the prevention and treatment of smallpox. Bull World Health Organ 27 (1962) 325-330
25. Kempe C.H., Berge T.O., and England B. Hyperimmune vaccinal gamma globulin; source, evaluation, and use in prophylaxis and therapy. Pediatrics 18 2 (1956) 177-188
26. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 100 16 (2003) 9458-9463